Oral bioavailability and disposition characteristics of irbesartan, an angiotensin antagonist, in healthy volunteers. 1998

N N Vachharajani, and W C Shyu, and T J Chando, and D W Everett, and D S Greene, and R H Barbhaiya
Department of Metabolism and Pharmacokinetics, Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, New Jersey 08540, USA.

Absolute oral bioavailability and disposition characteristics of irbesartan, an angiotensin II receptor antagonist, were investigated in 18 healthy young male volunteers. Subjects received [14C] irbesartan as a 30-minute intravenous infusion (50 mg), [14C] irbesartan orally as a solution (50 mg or 150 mg), or irbesartan capsule (50 mg). Irbesartan was rapidly and almost completely absorbed after oral administration, and exhibited a mean absolute oral bioavailability of 60% to 80%. Mean total body clearance was approximately 157 mL/min, and renal clearance was 3.0 mL/min. Volume of distribution at steady state was 53 L to 93 L, and terminal elimination half-life was approximately 13 to 16 hours. Hepatic extraction ratio was low (0.2). There were no major circulating metabolites, and approximately 80% of total plasma radioactivity was attributable to unchanged irbesartan. Regardless of route of administration, approximately 20% of dose was recovered in urine and the remainder in feces.

UI MeSH Term Description Entries
D008297 Male Males
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077405 Irbesartan A spiro compound, biphenyl and tetrazole derivative that acts as an angiotensin II type 1 receptor antagonist. It is used in the management of HYPERTENSION, and in the treatment of kidney disease. 2-N-Butyl-3-((2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)-1,3-diazaspiro(4,4)non-1-en-4-one,Aprovel,Avapro,BMS 186295,BMS-186295,Karvea,SR 47436,SR-47436,SR47436
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000804 Angiotensin II An octapeptide that is a potent but labile vasoconstrictor. It is produced from angiotensin I after the removal of two amino acids at the C-terminal by ANGIOTENSIN CONVERTING ENZYME. The amino acid in position 5 varies in different species. To block VASOCONSTRICTION and HYPERTENSION effect of angiotensin II, patients are often treated with ACE INHIBITORS or with ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS. Angiotensin II, Ile(5)-,Angiotensin II, Val(5)-,5-L-Isoleucine Angiotensin II,ANG-(1-8)Octapeptide,Angiotensin II, Isoleucine(5)-,Angiotensin II, Valine(5)-,Angiotensin-(1-8) Octapeptide,Isoleucine(5)-Angiotensin,Isoleucyl(5)-Angiotensin II,Valyl(5)-Angiotensin II,5 L Isoleucine Angiotensin II,Angiotensin II, 5-L-Isoleucine
D001682 Biological Availability The extent to which the active ingredient of a drug dosage form becomes available at the site of drug action or in a biological medium believed to reflect accessibility to a site of action. Availability Equivalency,Bioavailability,Physiologic Availability,Availability, Biologic,Availability, Biological,Availability, Physiologic,Biologic Availability,Availabilities, Biologic,Availabilities, Biological,Availabilities, Physiologic,Availability Equivalencies,Bioavailabilities,Biologic Availabilities,Biological Availabilities,Equivalencies, Availability,Equivalency, Availability,Physiologic Availabilities
D001713 Biphenyl Compounds Whitish aromatic crystalline organic compounds made up of two conjoined BENZENE rings. Compounds, Biphenyl
D013777 Tetrazoles

Related Publications

N N Vachharajani, and W C Shyu, and T J Chando, and D W Everett, and D S Greene, and R H Barbhaiya
November 1987, Journal of clinical pharmacology,
N N Vachharajani, and W C Shyu, and T J Chando, and D W Everett, and D S Greene, and R H Barbhaiya
January 2000, Drug metabolism and disposition: the biological fate of chemicals,
N N Vachharajani, and W C Shyu, and T J Chando, and D W Everett, and D S Greene, and R H Barbhaiya
January 2002, Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban,
N N Vachharajani, and W C Shyu, and T J Chando, and D W Everett, and D S Greene, and R H Barbhaiya
January 1994, Chirality,
N N Vachharajani, and W C Shyu, and T J Chando, and D W Everett, and D S Greene, and R H Barbhaiya
March 1989, Arzneimittel-Forschung,
N N Vachharajani, and W C Shyu, and T J Chando, and D W Everett, and D S Greene, and R H Barbhaiya
August 2001, Journal of clinical pharmacology,
N N Vachharajani, and W C Shyu, and T J Chando, and D W Everett, and D S Greene, and R H Barbhaiya
November 2002, Clinical pharmacology and therapeutics,
N N Vachharajani, and W C Shyu, and T J Chando, and D W Everett, and D S Greene, and R H Barbhaiya
January 2017, Frontiers in veterinary science,
N N Vachharajani, and W C Shyu, and T J Chando, and D W Everett, and D S Greene, and R H Barbhaiya
August 2008, Journal of clinical pharmacology,
N N Vachharajani, and W C Shyu, and T J Chando, and D W Everett, and D S Greene, and R H Barbhaiya
January 2014, Drug research,
Copied contents to your clipboard!